-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, 2022, Astellas announced that the Phase III clinical SPOTLIGHT of Claudin18.
2 antibody Zolbetuximab + chemotherapy in combination with Claudin18.
2-positive and HER2-negative recurrent metastatic gastric cancer reached the primary endpoint
.
SPOTLIGHT enrolled 566 patients with Claudin18.
2-positive and HER2-negative gastric cancer, and the study met the primary endpoint
of PFS.
In addition, the study also met the key secondary endpoint
of OS.
Originally developed by German biotech company Ganymed, Zolbetuximab was widely featured at the ASCO conference in 2016
.
That same year, Astellas acquired Ganymed for $1.
4 billion, acquiring Zolbetuximab
.
Ganymed was screened for monoclonal antibody by expression vector or cellular immunity, and IMAB362 recognized Claudin
The first extracellular domain
of 18.
2.
summary
summarySince gastric cancer is the second largest cancer in China after lung cancer, the progress of Zolbetuximab has attracted many domestic pharmaceutical companies to join the R&D competition
of this target drug.
It is worth noting that domestic pharmaceutical companies are in Claudin
In the R&D competition of 18.
2 targets, many new attempts have emerged, including monoclonal antibodies, bispecific antibodies, CAR-T, ADCs, etc.
, and many pharmaceutical companies have developed 2 or even more Claudin18.
2 targeted drugs
at the same time.
